RMC-6291
RMC-6291 is an orally active, covalent inhibitor of KRAS G12C (ON) that forms a tri-complex within tumor cells between KRAS G12C (ON) and cyclophilin A (CypA), thereby preventing KRAS G12C (ON) from signaling via steric blockade of RAS effector binding and eliciting deep and durable suppression of RAS pathway activity in KRAS G12C tumor models .
Product Specifications
CAS Number
2641998-63-0
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
1012.26
Molecular Formula
C55H78FN9O8
Notes
Research use only, not for human use.
Receptor
Kras
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
171494-ML490 100 µL
CD19 (B Lymphocyte Antigen CD19, B4, Differentiation Antigen CD19, Leu 12, Leu-12, MGC12802) (MaxLight 490) discontinued
Ask
View Details 
